The return of interest in nuclear energy has once again given Belgium “leverage” in the supply chain with tools available for innovative nuclear medicine treatments such as radioligand therapy, Stien Schrauwen, a member of energy minister Mathieu Bihet’s cabinet has said.

Schrauwen said an investigation into and production of radioligand therapy was “a strategic priority” with scientific value and a matter of national sovereignty in “a critical sector”.

Schrauwen said that in 2025, Belgium helped to treat almost 13 million patients worldwide by producing medical radioisotopes.

“Nuclear medicine is a true sector of excellence for our country,” she said. “We benefit from a unique ecosystem that brings together cutting-edge institutions, high-quality infrastructure, and internationally recognised expertise.

“This gives us a responsibility and an opportunity: to continue playing a leading role in Europe and around the world by making the most of our expertise. After all, behind these applications lie lives, hopes and care pathways.”